Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trimeris (TRMS) -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (86)	9/12/2000 5:30:18 PM
From: Ben Wa	Read Replies (1) \| Respond to of 108

you have an interesting conclusion. the analysis is IMO, overly simplistic, however you are entitled to your opinion. Issues you have not addressed include but are not limited to: duration of the patients response and the nature of the re-establishment of a detectable viral load, potential for additional therapies after a non T20 patient sees viral breakthrough compared to a T-20 arm. Additional considerations are the fact that anti-fusion technology is, (I hate to use the term) a technology platform, and as such is in the process of making its way into the treatment of areas outside of HIV. This firm also has a 2nd generation product on the way that could be very exciting. Of course, it may be possible that Lyndon Larouche could be right also about the etiology of HIV. Then, if it is really a plot, we may all be in deep doodoo.